TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 04/05/24

2024-04-05 13:53:08 ET More on Ovid Therapeutics Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for Ovid Therapeutics Financial information for Ovid Therapeutics Read the full article on Seeking Alpha For further det...

2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...

2024-04-05 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms ADZYNMA (apadamtase alfa /cinaxadamtase alfa) is the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for People with cTTP Takeda (...

2024-03-26 01:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...

2024-03-20 10:06:37 ET More on Puma Biotechnology Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript Puma Biotechnology dips after dismissal of its suit was granted by a federal jud...

− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (ALL) in Combination with Chemotherapy − First FDA Approval in Ph+ ALL Based on Novel Primary Endpoint of Minimal Residual Disease (MRD)-negati...

2024-03-19 07:41:32 ET More on Centogene, Takeda, etc. Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call...

2024-03-17 21:16:05 ET Summary Pfizer's stock has dropped over the last year+ due to declines in revenue and profit from Covid-related products. The company's non-Covid products have shown growth, indicating potential for continued future success. While the upcoming patent cli...